Bioventus Inc. (BVS)
Bioventus Statistics
Share Statistics
Bioventus has 65.37M shares outstanding. The number of shares has increased by 3.14% in one year.
| Shares Outstanding | 65.37M |
| Shares Change (YoY) | 3.14% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 68.87% |
| Shares Floating | 44.67M |
| Failed to Deliver (FTD) Shares | 424 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 922.37K, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 922.37K |
| Short % of Shares Out | 1.41% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is -2.11 and the forward PE ratio is 18.5. Bioventus's PEG ratio is 0.07.
| PE Ratio | -2.11 |
| Forward PE | 18.5 |
| PS Ratio | 0.64 |
| Forward PS | 1.1 |
| PB Ratio | 1.9 |
| P/FCF Ratio | 41.36 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Bioventus Inc. has an Enterprise Value (EV) of 702.66M.
| EV / Earnings | -4.5 |
| EV / Sales | 1.37 |
| EV / EBITDA | -30.46 |
| EV / EBIT | -8.6 |
| EV / FCF | 88.03 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 2.27.
| Current Ratio | 1.53 |
| Quick Ratio | 1.01 |
| Debt / Equity | 2.27 |
| Total Debt / Capitalization | 69.46 |
| Cash Flow / Debt | 0.04 |
| Interest Coverage | -2.01 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -13.28%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -13.28% |
| Revenue Per Employee | $497,422.33 |
| Profits Per Employee | $-151,679.61 |
| Employee Count | 1,030 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.02 |
Taxes
| Income Tax | 85K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 105.89% in the last 52 weeks. The beta is 0.86, so Bioventus's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | 105.89% |
| 50-Day Moving Average | 10.29 |
| 200-Day Moving Average | 9.59 |
| Relative Strength Index (RSI) | 47.35 |
| Average Volume (20 Days) | 277.8K |
Income Statement
In the last 12 months, Bioventus had revenue of 512.35M and earned -156.23M in profits. Earnings per share was -2.49.
| Revenue | 512.35M |
| Gross Profit | 328.19M |
| Operating Income | -81.72M |
| Net Income | -156.23M |
| EBITDA | -23.07M |
| EBIT | -81.72M |
| Earnings Per Share (EPS) | -2.49 |
Balance Sheet
The company has 36.96M in cash and 394.85M in debt, giving a net cash position of -357.88M.
| Cash & Cash Equivalents | 36.96M |
| Total Debt | 394.85M |
| Net Cash | -357.88M |
| Retained Earnings | -321.54M |
| Total Assets | 769.49M |
| Working Capital | 87.2M |
Cash Flow
In the last 12 months, operating cash flow was 15.34M and capital expenditures -7.36M, giving a free cash flow of 7.98M.
| Operating Cash Flow | 15.34M |
| Capital Expenditures | -7.36M |
| Free Cash Flow | 7.98M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 64.06%, with operating and profit margins of -15.95% and -30.49%.
| Gross Margin | 64.06% |
| Operating Margin | -15.95% |
| Pretax Margin | -23.64% |
| Profit Margin | -30.49% |
| EBITDA Margin | -4.5% |
| EBIT Margin | -15.95% |
| FCF Margin | 1.56% |
Dividends & Yields
BVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.58% |
| FCF Yield | 1.2% |
Analyst Forecast
The average price target for BVS is $15, which is 48.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15 |
| Price Target Difference | 48.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.83 |
| Piotroski F-Score | 5 |